Drilldown: Medicines

Nav

Choose a table:

Medicines (732)

Medicines > classes

: Anticonvulsant

or Cathinone

or [[:Category:Opioid_analgesics|Opioid analgesic]]

Use the filters below to narrow your results.

3-MMC (1) · Brivaracetam (1) · Butylone (1) · Cannabidiol (1) · Cathinone (1) · Cenobamate (1) · Clobazam (1) · Ephylone (1) · Eslicarbazepine (1) · Ethcathinone (1) · Ethosuximide (1) · Ethylone (1) · Felbamate (1) · Fenfluramine (1) · Fosphenytoin (1) · Hexedrone (1) · Lacosamide (1) · Mephedrone (1) · Methcathinone (1) · Methylone (1) · Mexedrone (1) · N-Ethylhexedrone (1) · N-Ethylpentedrone (1) · Oxycodone / Acetaminophen (1) · Oxycodone / Aspirin (1) · Pentedrone (1) · Perampanel (1) · Phenobarbital (1) · Phenytoin (1) · Rufinamide (1) · Stiripentol (1) · Tiagabine (1) · Valproic acid (1) · Vigabatrin (1) · Zonisamide (1)

None (14) · Aptiom (1) · Banzel (1) · Briviact (1) · Cerebyx (1) · Depakote (1) · Diacomit (1) · Dilantin (1) · Epidiolex (1) · Felbatol (1) · Fintepla (1) · Fycompa (1) · Gabitril (1) · Luminal (1) · Onfi (1) · Percocet, Endocet, Roxicet, Tylox, Primlev (1) · Percodan (1) · Sabril (1) · Vimpat (1) · Xcopri (1) · Zarontin (1) · Zonegran (1)

AMPA receptor antagonist (1) · Cathinone analogue; monoamine reuptake inhibitor (2) · GABA enhancer; sodium channel blocker; histone deacetylase inhibitor (1) · GABA reuptake inhibitor (GAT-1 blocker) (1) · GABAA positive allosteric modulator (1) · GABAA positive allosteric modulator; lactate dehydrogenase inhibitor (1) · GABAA potentiator and direct activator (1) · Irreversible GABA-T inhibitor (1) · Monoamine releasing agent (4) · Monoamine releasing agent; active ingredient in khat (1) · Multiple mechanisms; GPR55 antagonist; TRPV1 agonist (1) · NMDA antagonist; GABAA potentiator (1) · Norepinephrine and dopamine releasing agent (1) · Norepinephrine/dopamine releasing agent (1) · Norepinephrine/dopamine reuptake inhibitor (1) · Prodrug of phenytoin; sodium channel blocker (1) · Serotonin releaser; sigma-1 agonist (1) · Serotonin releasing agent; monoamine reuptake inhibitor (1) · Serotonin/norepinephrine/dopamine releasing agent (3) · Slow-inactivation sodium channel enhancer; CRMP-2 ligand (1) · Sodium channel blocker (2) · Sodium channel blocker; GABAA positive allosteric modulator (1) · Sodium channel modulator (1) · Sodium/T-type calcium channel blocker; carbonic anhydrase inhibitor (1) · SV2A ligand (higher affinity than levetiracetam) (1) · T-type calcium channel blocker (1) · '"`UNIQ--vote-000014DD-QINU`"' The combination is the most-prescribed opioid analgesic in the US for moderate-to-severe acute pain. CPIC PGx guidance addresses CYP2D6-driven exposure variation'"`UNIQ--ref-000014DE-QINU`"'. (1) · '"`UNIQ--vote-000014F7-QINU`"' Falling out of favor for acute pain due to aspirin's GI bleeding and antiplatelet effects compared with acetaminophen-opioid combinations; still used in selected indications'"`UNIQ--ref-000014F8-QINU`"'. (1)

None (33) · '"`UNIQ--vote-000014DF-QINU`"', '"`UNIQ--vote-000014E0-QINU`"', '"`UNIQ--vote-000014E1-QINU`"' (1) · '"`UNIQ--vote-000014F9-QINU`"' (1)

None (33) · 1 tablet (4.8355 mg oxycodone / 325 mg aspirin) PO every 6 hours as needed (1) · 5 mg / 325 mg PO every 4-6 hours as needed; total acetaminophen <3 g/d (1)

None (33) · 4.8355 mg oxycodone / 325 mg aspirin tablets (1) · Oxycodone/acetaminophen 2.5/325, 5/325, 7.5/325, 10/325 mg tablets; 5/325 mg/5 mL solution (1)

None (33) · Acetaminophen 4 g/d absolute (3 g/d conservative); oxycodone titrated to effect (1) · Aspirin GI/bleeding-limited; oxycodone titrated to effect (1)

None (33) · Oral (2)

None (33) · 10-30 minutes (1) · 15-30 minutes (1)

None (33) · 4-6 hours (2)

None (33) · Oxycodone 3-5 hours; acetaminophen 1-3 hours'"`UNIQ--ref-000014E2-QINU`"' (1) · Oxycodone 3-5 hours; aspirin (acetyl group) 15-20 minutes, salicylate 2-3 hours at therapeutic doses'"`UNIQ--ref-000014FA-QINU`"' (1)

None (33) · Oxycodone 60-87%; aspirin 50-75%'"`UNIQ--ref-000014FB-QINU`"' (1) · ~60-87% oxycodone (high and predictable, less CYP-genotype-dependent than codeine or hydrocodone); 85-98% acetaminophen'"`UNIQ--ref-000014E3-QINU`"' (1)

None (33) · Avoid; aspirin teratogenicity concerns plus opioid neonatal withdrawal.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) · Limited use in pregnancy; chronic third-trimester opioid exposure produces neonatal opioid withdrawal syndrome and respiratory depression at delivery.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1)

None (33) · [[USLegal:Schedule II|Schedule II controlled substance]] in US (1) · [[USLegal:Schedule II|Schedule II controlled substance]] in US. Acetaminophen content limited to ≤325 mg per dosage unit (FDA 2014) (1)